HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Looking For Details As Legislation Looks Likely On Hemp Ingredients' Use In Supplements

Executive Summary

Whether lawmakers will favor legislation aligning with FDA’s thinking or hemp industry’s preferences isn’t known, says Jonathan Miller, US Hemp Roundtable general counsel. “We're feeling pretty confident that something's going to happen.”

You may also be interested in...



US Regulators’ Warnings Letters Reheat Concerns About Allowing Hemp Ingredients In Food

FDA long has doubted safety of using cannabinoids in food products while saying it’s open to finding a pathway for allowing hemp-derived ingredients’ use in supplements. Warning letters to six businesses could be exhibit A for FDA’s argument against cannabinoids’ use in food.

US Hemp Industry Group Rings Alarm With Congress About FDA’s Safety Conclusions

US Hemp Roundtable general counsel cautions congressional leaders about “agency’s misguided use of incomplete safety data as the basis for its continued refusal to regulate CBD as a dietary supplement or food additive.”

Details Dished On Regulatory Pathway US FDA’s Developing For Lawful Hemp In Supplements

Pathway separate from FDA’s regulation of drugs and food would include rules on content limits, labeling, disclosure of ingredients– including assurances of no contaminants, and requirements to mitigate accidental ingestion.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel